Pediatric Cardiology

, Volume 34, Issue 2, pp 444–446 | Cite as

Extensive Coronary Aneurysms With Thrombosis in Resistant Kawasaki Disease

Case Report
First Online:
Received:
Accepted:

Abstract

Giant coronary artery aneurysms that occur in 0.5 to 1% of patients with Kawasaki disease can be fatal if associated with thrombosis. Some patients may show persistent inflammation and fever despite treatment with repeated doses of intravenous immunoglobulin (IVIG), steroids, and aspirin. This report describes an infant boy with resistant Kawasaki disease who presented with extensive coronary artery involvement and coronary thrombosis. His inflammation was not controlled with multiple doses of IVIG, parenteral and oral steroids, or high-dose aspirin, and he finally needed infliximab, a monoclonal antibody against tumor necrosis factor alpha. The progression of coronary thrombosis was arrested by the platelet glycoprotein 2b/3a receptor blocker, abciximab, during the acute phase of the disease.

Keywords

Abciximab Coronary aneurysm Coronary thrombus Infliximab Intravenous immunoglobulin Resistant Kawasaki disease 
This is a preview of subscription content, log in to check access.

Supplementary material

246_2012_285_MOESM1_ESM.avi (1.9 mb)
Supplementary material 1 (AVI 1961 kb)
246_2012_285_MOESM2_ESM.avi (1.7 mb)
Supplementary material 2 (AVI 1732 kb)
246_2012_285_MOESM3_ESM.avi (1.5 mb)
Supplementary material 3 (AVI 1556 kb)

References

  1. 1.
    Burns JC, Mason WH, Hauger SB, Janai H, Bastian JF, Wohrley JD et al (2005) Infliximab treatment for refractory Kawasaki syndrome. J Pediatr 146:662–667PubMedCrossRefGoogle Scholar
  2. 2.
    Burns JC, Best BM, Mejias A, Mahony L, Fixler DE, Jafri HS et al (2008) Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease. J Pediatr 153:833–838PubMedCrossRefGoogle Scholar
  3. 3.
    Horigome H, Sekijima T, Miyamoto T (1997) Successful thrombolysis with intracoronary administration of tissue plasminogen activator in an infant with Kawasaki disease. Heart 78:517–518PubMedGoogle Scholar
  4. 4.
    Kato H, Sugimura T, Akagi T, Sato N, Hashino K, Maeno Y (1996) Long-term consequences of Kawasaki disease: a 10- to 21-year follow-up study of 594 patients. Circulation 94:1379–1385PubMedCrossRefGoogle Scholar
  5. 5.
    Koren G, Lavi S, Rose V, Rowe R (1986) Kawasaki disease: review of risk factors for coronary aneurysms. J Pediatr 108:388–392PubMedCrossRefGoogle Scholar
  6. 6.
    Mori M, Imagawa T, Yasui K, Kanaya A, Yokota S (2000) Predictors of coronary artery lesions after intravenous gamma-globulin treatment in Kawasaki disease. J Pediatr 137:177–180PubMedCrossRefGoogle Scholar
  7. 7.
    Takahashi M, Mason W, Lewis AB (1987) Regression of coronary aneurysms in patients with Kawasaki syndrome. Circulation 75:387–394PubMedCrossRefGoogle Scholar
  8. 8.
    Williams RV, Wilke VM, Tani LY, Minich LL (2002) Does abciximab enhance regression of coronary aneurysms resulting from Kawasaki disease? Pediatrics 109:E4PubMedCrossRefGoogle Scholar
  9. 9.
    Yeo Y, Kim T, Ha K, Jang G, Lee J, Lee K et al (2009) Incomplete Kawasaki disease in patients younger than 1 year of age: a possible inherent risk factor. Eur J Pediatr 168:157–162PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.Department of Pediatric CardiologyMIOT HospitalChennaiIndia

Personalised recommendations